# reload+after+2024-01-23 20:46:28.003147
address1§650 Chapel Street
address2§Suite 0403 Level 4
city§South Yarra
state§VIC
zip§3141
country§Australia
phone§61 3 9826 0399
fax§61 3 9824 0083
website§https://opthea.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
fullTimeEmployees§24
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Megan  Baldwin M.A.I.C.D., MAICD, Ph.D.', 'age': 49, 'title': 'Founder, Chief Innovation Officer & Executive Director', 'yearBorn': 1974, 'fiscalYear': 2023, 'totalPay': 599729, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Judith J. Robertson B.A., M.B.A.', 'age': 63, 'title': 'Chief Commercial Officer', 'yearBorn': 1960, 'fiscalYear': 2023, 'totalPay': 588590, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen  Adams CPA', 'age': 52, 'title': 'VP of Finance & Company Secretary', 'yearBorn': 1971, 'fiscalYear': 2023, 'totalPay': 305145, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Frederic  Guerard M.S., Pharm.D.', 'age': 51, 'title': 'Chief Executive Officer', 'yearBorn': 1972, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter F. Lang M.B.A.', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1972, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael  Gerometta Ph.D.', 'age': 59, 'title': 'Head of Chemistry, Manufacturing & Controls Development', 'yearBorn': 1964, 'fiscalYear': 2023, 'totalPay': 133828, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bruno  Gagnon BPHARM, M.Sc.', 'age': 55, 'title': 'Senior Vice President of Global Clinical Operations', 'yearBorn': 1968, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kenneth  Sall', 'title': 'Chief Medical Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§6
compensationRisk§10
shareHolderRightsRisk§10
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.765
priceToSalesTrailing12Months§709.43854
currency§USD
dateShortInterest§1702598400
exchange§NMS
quoteType§EQUITY
shortName§Opthea Limited
longName§Opthea Limited
firstTradeDateEpochUtc§1602855000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d6466988-2d28-391f-9a0f-e0926f80e751
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.98
targetLowPrice§7.99
targetMeanPrice§12.82
targetMedianPrice§12.99
recommendationMean§1.3
recommendationKey§strong_buy
numberOfAnalystOpinions§6
quickRatio§5.109
grossMargins§0.56700003
ebitdaMargins§0.0
trailingPegRatio§None
